echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Anhui issued the work plan for centralized treatment of Chinese herbal pieces, with 6 categories as key varieties

    Anhui issued the work plan for centralized treatment of Chinese herbal pieces, with 6 categories as key varieties

    • Last Update: 2020-02-19
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    [industry trends of pharmaceutical network] on February 11, Anhui Provincial Drug Administration issued a notice on suspending the production of two Chinese Herbal Pieces companies According to the announcement, according to the complaint, Bozhou market supervision and Administration Bureau carried out a causal (flight) inspection on two enterprises in Bozhou, and found that the two enterprises had serious violations of GMP, and there were quality and safety risks and hidden dangers in drug production In order to control the risks and hidden dangers of drug quality and safety, the bureau decided to suspend the production of Chinese herbal pieces of these two enterprises according to relevant regulations This announcement has attracted the attention and discussion of the industry Many people believe that in 2020, the supervision of the Chinese Herbal Pieces industry will be strengthened, and some enterprises that do not meet the GMP specifications will gradually withdraw from the market, and the industry will face a greater test In fact, there have been many problems in the Chinese herbal medicine industry, such as market disorder, quality and safety Anhui Province, as a large province of Chinese herbal medicine resources and production and processing of Chinese herbal pieces, has a long history of processing Chinese herbal pieces and a wide range of clinical applications In recent years, it is also strengthening the supervision and management of Chinese herbal pieces Recently, the Anhui drug regulatory bureau issued the work plan for centralized treatment of Chinese Herbal Pieces in Anhui Province (hereinafter referred to as the plan), and decided to carry out 11 month centralized treatment of Chinese Herbal Pieces in the whole province from February to December 2020, further standardize the production and circulation order of Chinese Herbal Pieces in the whole province, and strengthen the supervision of Chinese Herbal Pieces for epidemic prevention and control According to the plan, this centralized treatment will highlight key varieties, key enterprises and key problems, comprehensively use supervision and inspection, supervision and sampling, risk control, administrative punishment and other means, strictly investigate and punish the illegal behaviors in the production, operation and use of Chinese herbal pieces, actively explore and innovate the management mode of Chinese herbal pieces, and promote the high-quality development of the province's Chinese herbal industry The plan divides the centralized treatment of Chinese herbal pieces into several parts The key varieties are 6 categories: Chinese Herbal Pieces for epidemic prevention and control; Chinese Herbal Pieces for 2019 and 2020; Chinese herbal pieces with high disqualification rate for 2018 and 2019; Chinese Herbal Pieces for precious and fine herbs; Chinese herbal pieces involved in the "top ten Anhui medicines"; Chinese Pharmacopoeia (2020 version) and Anhui standard for processing of Chinese herbal pieces (2019 version) with changed test methods In addition, according to the plan, enterprises with more complaints and reports; enterprises whose GMP certificates have been withdrawn or GSP certificates have been revoked in the past three years and whose production and sales have been suspended; single drugstores, individual clinics, etc., will be focused by the provincial food and drug administration Enterprises that seriously violate GMP and GSP will face warnings, interviews, rectification within a time limit, suspension of production and sales At present, novel coronavirus pneumonia has been actively responded to by Bozhou It is clear that the city will carry out centralized control of Chinese herbal medicine in the city from February 16th to December, further standardize the production and circulation order of Chinese herbal medicine, and strengthen the supervision of the new crown pneumonia epidemic prevention and control with Chinese herbal medicine   It is reported that the municipal market supervision and Administration Bureau will set up an inspection team to conduct full coverage supervision and inspection on the production enterprises of Chinese herbal pieces (including Chinese herbal formula particles) within its jurisdiction, pay close attention to the varieties of Chinese herbal pieces used for epidemic prevention and control, as well as the varieties of original Chinese herbal medicines with rising prices and short supply, carry out targeted supervision work, prevent risks, eliminate hidden dangers, and always maintain a high-pressure state of strict inspection and control Potential  
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.